The agreement to gain rights outside of China to a portfolio of early-stage experimental obesity and diabetes drugs could be ...

By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...

By Andrew MacAskill and Maggie Fick BEIJING/LONDON, Jan 29 (Reuters) - UK drugmaker AstraZeneca will invest $15 billion in ...

By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease ...

Executives from Airbus, AstraZeneca and HSBC are joining Prime Minister Keir Starmer on a rare China visit, highlighting the ...

AstraZeneca announces a $15B China investment through 2030 to expand manufacturing and R&D in cell therapy and radioconjugates—read the full update now.

AstraZeneca ( AZN) has struck an obesity drug deal with Chinese company CSPC Pharmaceutical Group ( CHJTF) worth up to $18.5B ...

British pharmaceutical group AstraZeneca said Thursday that it would invest $15 billion in China through 2030 to expand its ...

AstraZeneca has returned to CSPC with a licensing deal for the Chinese company’s monthly injectables for obesity.

This investment coincides with China’s burgeoning presence in the pharmaceutical industry, driven by an uptick in innovative medicines R&D.